By the InsightArea Editorial Team
Merck reported $18.1 billion in worldwide sales for the third quarter of 2026, up 5% from a year earlier. Its cancer medicines Keytruda and Keytruda Qlex accounted for $8.6 billion of that total. That combination captures a central question for investors: how does a company sustain growth when one product family represents such a large share of its business?
The company’s results, released October 29 at 6:39 a.m. Eastern Daylight Time, show both the strength of a major medicine franchise and the difficulty of replacing it over time. Merck also raised the midpoint of its full-year sales outlook. None of these figures, however, tells investors by itself what the shares are worth.
Why is Keytruda so important to Merck?
Keytruda and Keytruda Qlex are cancer immunotherapy products based on pembrolizumab. The company reported combined quarterly sales of approximately $8.6 billion, a 6% increase from the corresponding quarter a year earlier. Keytruda Qlex contributed $830 million to the combined figure. These are worldwide sales reported in US dollars, not profit attributable to each product.
Using the company’s rounded figures, the franchise represented roughly 48% of total quarterly sales. That is a concentration, not a statement that all of Merck’s earnings come from one product. The company has other pharmaceutical products, an animal health business, research spending, manufacturing costs and other activities that affect its financial results.
Concentration can be an advantage while a successful medicine is growing. An established product may benefit from approvals across multiple uses, physician familiarity and a large distribution network. But investors also need to consider what happens as exclusivity changes, competing treatments emerge or clinical practice evolves. Large current sales make future replacement a significant challenge.
What does the new formulation change?
The company reports Keytruda Qlex separately within the combined franchise total. A different formulation can matter for how a medicine is administered and how a company positions its products. That does not mean it automatically eliminates competitive or patent risks, nor should a sales figure be mistaken for an independent clinical comparison.
For investors, the useful question is how much of the newer formulation’s sales represent growth in the overall franchise and how much reflects patients or revenue moving between formulations. The quarterly announcement provides sales figures, but those figures alone do not show a complete patient-by-patient migration story. Further disclosures and longer trends would be needed.
Another question is how the economics of a medicine change across markets. Sales can be affected by reimbursement, net pricing, purchasing patterns, competition and exchange rates. A high-profile launch can generate attention while contributing a smaller amount to company-wide revenue than an established treatment. Comparing the two requires more than reading a headline.
Where else is growth coming from?
Merck reported quarterly sales of $694 million for Winrevair, up 93% year over year, and approximately $1.7 billion for animal health, up 4%. These contributions are meaningful, but they start from different bases. A very high percentage growth rate for a smaller product does not necessarily add more dollars than modest growth for a much larger one.
A simple hypothetical shows why. If a product with $100 in sales doubles, it adds $100. If another product with $1,000 in sales grows 15%, it adds $150. The second product has the lower percentage growth rate but the larger increase in absolute sales. Neither example describes a forecast for Merck; it illustrates why investors need both the base and the growth rate.
Timing can complicate the comparison as well. Merck said pharmaceutical sales benefited by approximately $550 million from the timing of purchases. Purchasing shifts can move revenue between quarters without representing an equivalent change in underlying patient demand. The same issue can appear in the other direction in a later period.
Why did reported earnings fall while sales rose?
Merck reported quarterly GAAP earnings per share of $2.04 and non-GAAP earnings per share of $2.49. The company also reported that GAAP net income declined from the same quarter a year earlier. Revenue and profit do not have to move together: changes in costs, transaction charges, tax and other items can affect earnings even when sales increase.
The distinction between GAAP and non-GAAP measures matters. GAAP follows a standardized accounting framework; adjusted measures reflect the company’s specified exclusions. Adjustments can help readers understand particular one-time events, but they can also remove expenses that are economically important. Investors should inspect the reconciliation rather than assume that either figure alone tells the whole story.
Both quarterly EPS measures included a one-time charge of $0.12 per share related to a licensing agreement, according to the release. A charge described as one-time can still represent real spending. In a research-driven industry, acquisitions and licensing may be central to renewing a product portfolio, so the pattern of such transactions deserves attention over several years.
What does the outlook actually say?
Merck narrowed its expected 2026 worldwide sales range to $66.8 billion–$67.3 billion and raised the midpoint. It also forecast full-year non-GAAP earnings of $2.77–$2.82 per share. The company says that outlook includes substantial charges associated with acquisitions and the licensing agreement. The figures are management’s forecast, not an outcome already achieved.
It would be misleading to compare a single quarter’s EPS mechanically with the full-year adjusted outlook without examining the periods and charges involved. Full-year figures incorporate earlier quarters and the company’s assumptions for the rest of the year. Exchange rates and the timing of transactions can also affect the comparison.
Guidance gives investors a framework for tracking management’s expectations, but it cannot remove uncertainty. Actual results may differ because of clinical trials, regulatory decisions, competition, manufacturing, pricing, currencies or future business-development transactions. The company itself notes that its outlook excludes additional significant potential transactions.
What should an investor watch next?
Start with the established franchise: track overall Keytruda and Qlex sales together, then examine what the company discloses about the newer formulation. A rising share for Qlex is not automatically the same thing as an expanding total market. Sales growth and the sustainability of that growth deserve separate questions.
Next, follow the rest of the portfolio in dollar terms as well as percentages. Products with fast growth may eventually become material, but investors should assess whether their combined contribution can offset pressure elsewhere. Animal health offers a different business exposure, though it is not immune to its own operating and competitive risks.
Finally, separate a scientific milestone from a commercial result. An encouraging clinical trial or a regulatory filing is not the same as an approval, and an approval is not a guarantee of strong sales. Each stage has its own uncertainties. The reported pipeline progress is therefore worth following without treating investigational products as proven future revenue.
Merck’s quarter offers a clear lesson in concentration: a strong current franchise can fund research and support sales today while making the question of future diversification more important. How the company manages that transition is a matter for continued observation, not a conclusion that can be settled by one earnings release.
This article is educational and is not personalized investment advice.
Explore the book: 
How to Do Hard Things: The Discomfort Trap
Comments are closed.